Pharmaceutical Technology53 分钟
ANXV by Annexin Pharmaceuticals for Retinal Vein Occlusion: Likelihood of Approval
ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.
Pharmaceutical Technology58 分钟
Tigilanol tiglate by QBiotics Group for Squamous Cell Carcinoma: Likelihood of Approval
Tigilanol tiglate is under clinical development by QBiotics Group and currently in Phase I for Squamous Cell Carcinoma.